Immunotherapy News and Research

Latest Immunotherapy News and Research

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

A study published today in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA deletions associated with a range of diseases and disorders as well as aging. This approach, which relies on Droplet Digital PCR (ddPCR-) technology, will help researchers explore mtDNA deletions as potential disease biomarkers.

4 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Women in their 40s and 50s are hospitalized more than twice for asthma attack

Asthma is a disease that mostly affects young boys and adult women. And according to a new study, women in their 40s and 50s with asthma are hospitalized more than twice as often as men in the same age group. The 10-year study is published in the September issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

3 Sep 2013

ddPCR technology can be used to reproducibly quantify microRNA in plasma

A study published online in Nature Methods today demonstrated that Droplet Digital PCR (ddPCR-) technology can be used to precisely and reproducibly quantify microRNA (miRNA) in plasma and serum across different days, paving the way for further development of miRNA and other nucleic acids as circulating biomarkers.

2 Sep 2013

LLS survey uncovers alarming lack of knowledge among U.S. adults about blood cancers

Less than one half (46%) of adults polled in a new survey believe that blood cancers are one of three leading causes of cancer death in the U.S. In fact, blood cancers are the third leading cause of cancer death, behind cancers of the respiratory system, including lung cancer, and cancers of the digestive system, including colorectal cancer.

30 Aug 2013

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.

30 Aug 2013

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

Coffee consumption is associated with a lower risk of prostate cancer recurrence and progression, according to a new study by Fred Hutchinson Cancer Research Center scientists that is online ahead of print in Cancer Causes & Control.

27 Aug 2013

Seven researchers to receive grants from ASTRO to advance radiation oncology research

The American Society for Radiation Oncology (ASTRO) has selected seven (7) leading researchers who will receive a total of $675,000 in awards and grants to advance radiation oncology research.

23 Aug 2013

Novel Approach Developed On Antitumor Immunotherapy

...

22 Aug 2013

New type of cancer immunotherapy harnesses body's immune system to attack tumors

By carefully adjusting the function of crucial immune cells, scientists may have developed a completely new type of cancer immunotherapy—harnessing the body's immune system to attack tumors. To accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responses.

19 Aug 2013

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Advaxis, Inc., (OTCQB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer.

17 Aug 2013

GHI research aims to target breast cancer stem-like cells using immunotherapy

New hope is on its way for the fight against breast cancer as Griffith Health Institute research aims to target the disease with immune-based therapies.

16 Aug 2013

New treatment technique uses nanoparticles to attack cancer

Researchers at the University of Georgia are developing a new treatment technique that uses nanoparticles to reprogram immune cells so they are able to recognize and attack cancer. The findings were published recently in the early online edition of ACS Nano.

16 Aug 2013

Proton therapy provides organ-sparing treatment option for children with neuroblastoma

Proton therapy, using high-energy subatomic particles, may offer a precise, organ-sparing treatment option for children with high-risk forms of neuroblastoma. For patients in a new study of advanced radiation treatment, proton therapy spared the liver and kidneys from unwanted radiation, while zeroing in on its target.

14 Aug 2013

Study finds increased ADHD risk in children who have allergy and asthma

The number of children being diagnosed with attention-deficit disorder (ADHD), allergy and asthma is increasing in the United States. And according to a new study, there might be a link between the growth of these three conditions.

14 Aug 2013

NW Bio receives decision to continue Phase III clinical trial on brain cancer in Germany

Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.

12 Aug 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Women in their 40s and 50s are hospitalized more than twice for asthma attack

ddPCR technology can be used to reproducibly quantify microRNA in plasma

LLS survey uncovers alarming lack of knowledge among U.S. adults about blood cancers

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

Seven researchers to receive grants from ASTRO to advance radiation oncology research

Novel Approach Developed On Antitumor Immunotherapy

New type of cancer immunotherapy harnesses body's immune system to attack tumors

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

GHI research aims to target breast cancer stem-like cells using immunotherapy

New treatment technique uses nanoparticles to attack cancer

Proton therapy provides organ-sparing treatment option for children with neuroblastoma

Study finds increased ADHD risk in children who have allergy and asthma

NW Bio receives decision to continue Phase III clinical trial on brain cancer in Germany

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Cancer-linked mitosis: an interview with Professor Scott Kern, Johns Hopkins University School of Medicine

UCLA researchers combine cellular and gene therapies to develop treatment for breast cancer

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in